| Revenue Disaggregation |
| Note 10. |
Revenue Disaggregation |
The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.
The following table presents the Company’s
disaggregated revenues by revenue source:
| Schedule of disaggregated revenues by revenue source |
|
|
|
|
|
|
|
|
| |
|
Three Months Ended December 31, |
|
Nine Months Ended December 31, |
| |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| Human Care |
|
$ |
3,052,000 |
|
|
$ |
2,461,000 |
|
|
$ |
8,886,000 |
|
|
$ |
7,286,000 |
|
| Animal Care |
|
|
376,000 |
|
|
|
621,000 |
|
|
|
1,176,000 |
|
|
|
1,688,000 |
|
| Service and Royalty |
|
|
136,000 |
|
|
|
56,000 |
|
|
|
472,000 |
|
|
|
322,000 |
|
| |
|
$ |
3,564,000 |
|
|
$ |
3,138,000 |
|
|
$ |
10,534,000 |
|
|
$ |
9,296,000 |
|
The following table shows the Company’s
revenues by geographic region:
| Schedule of revenues by geographic region |
|
|
|
|
|
|
|
|
| |
|
Three Months Ended December 31, |
|
Nine Months Ended December 31, |
| |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| United States |
|
$ |
614,000 |
|
|
$ |
868,000 |
|
|
$ |
1,930,000 |
|
|
$ |
2,214,000 |
|
| Europe |
|
|
1,257,000 |
|
|
|
1,217,000 |
|
|
|
3,943,000 |
|
|
|
3,488,000 |
|
| Asia |
|
|
579,000 |
|
|
|
522,000 |
|
|
|
1,832,000 |
|
|
|
1,730,000 |
|
| Latin America |
|
|
829,000 |
|
|
|
368,000 |
|
|
|
2,174,000 |
|
|
|
1,165,000 |
|
| Rest of the World |
|
|
285,000 |
|
|
|
163,000 |
|
|
|
655,000 |
|
|
|
699,000 |
|
| Total |
|
$ |
3,564,000 |
|
|
$ |
3,138,000 |
|
|
$ |
10,534,000 |
|
|
$ |
9,296,000 |
|
|